Pharmaids Pharmaceuticals Ltd
NSE: BSE: 524572
₹32.01
(-3.58%)
Sun, 29 Mar 2026, 06:54 pm
Market Cap1.13B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KPharmaids Pharmaceuticals Analysis
dividend
- Unable to evaluate Pharmaids Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Pharmaids Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Pharmaids Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Pharmaids Pharmaceuticals has no debt, it does not need to be covered by operating cash flow.
- Pharmaids Pharmaceuticals has no debt, it does not need to be covered by short term assets.
- Pharmaids Pharmaceuticals's cash and other short term assets cover its long term commitments.
- Pharmaids Pharmaceuticals has no debt compared to 5 years ago when it was 18.3%.
- Pharmaids Pharmaceuticals has no debt, therefore coverage of interest payments is not a concern.
- Pharmaids Pharmaceuticals has no debt.
- Low level of unsold assets.
- Pharmaids Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 32% each year.
- Pharmaids Pharmaceuticals has less than a year of cash runway based on current free cash flow.
management
- The average tenure for the Pharmaids Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
misc
- Pharmaids Pharmaceuticals is not covered by any analysts.
- BSE:524572 has not traded for 8 days.
past
- Unable to compare Pharmaids Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Pharmaids Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Pharmaids Pharmaceuticals has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Pharmaids Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Pharmaids Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Pharmaids Pharmaceuticals's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Pharmaids Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Pharmaids Pharmaceuticals is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Pharmaids Pharmaceuticals is loss making, we can't compare the value of its earnings to the India market.
- BSE:524572 is down -4.8% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524572 is down -4.8% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800